In summary, these results indicate that inhibition of PARP combined with modulation of the cholesterol biosynthesis pathway—either affecting LSS activity or more strongly by inhibiting HMGCR with statins—can lead to increased cell death of some tumor types, particularly tumor cells sensitive to modulation of cholesterol metabolism, such as TNBC and/or highly metastatic tumors (Fig. 4E). Here, PARP1 is linked to neoplasm.